study for an investigational product.
Content on this website is intended for U.S. Residents only.
If you or someone you know has been diagnosed with Non-Hodgkin Lymphoma (NHL) knowing all your options is important. Clinical trials help to expand the knowledge about diseases like NHL, however further medical research is needed to uncover more possibilities.
We are currently testing an investigational product for NHL which may impact your disease. To see if you qualify for this study, please answer a brief survey.
This clinical study will compare the effectiveness of the investigational medication (called ABP 798) with Rituximab.
This study will also evaluate the safety of ABP 798. Once enrolled in the study you may receive ABP 798 or Rituximab. A test is then required to see if your body is having a reaction (producing antidrug antibodies) to ABP 798 or Rituximab. In addition, we will measure the amount of ABP 798 in the your bloodstream as well as the resulting effect ABP 798 has on your body. Study required procedures and administered study drug will be provided at no cost to qualified participants.
If you’re interested in participating, please fill out a brief survey to see if you’re eligible.
1. If you meet the requirements and choose to proceed you will need to sign a consent form.
2. You will schedule and attend a screening visit to make sure you meet all study requirements. This visit will include a full medical history and physical exam along with other diagnostic tests.
3. If you pass all of the assessments, and your eligibility is confirmed and you decide to participate, the study will last up to 32-weeks and will involve up to 8 scheduled visits with your study doctor.
4. You will receive the study drug once weekly for 4-weeks and then at weeks 12 and 20.
5. You can decide to end your participation in the study at any time, for any reason – even after you’re enrolled.
To participate in this study:
1. You must be 18 years ore age or older
2. Diagnosed with Grade 1, 2 or 3a Follicular B-Cell Non-Hodgkin Lymphoma
3. You can be male or female
4. You also need to meet medical requirements including adequate kidney and liver function and more
Before a new medication is made available to the public, it must first be tested in clinical studies to ensure it is both safe and effective – making clinical studies necessary and important to everyone’s health and well-being.
In a clinical study, patients receive investigational products like ABP 798, while researchers closely monitor their safety and progress. Pharmaceutical and biotechnology companies must test their investigational medications very carefully before applying to a regulatory agency for approval to make it available to the public.
There are strict rules in place to protect all patients in a clinical study. Every study must follow a detailed plan, which is called a protocol. If you’re interested in participating, the study will be fully explained to you and your questions will be answered.
The most common single type of low-grade non-Hodgkin lymphoma, follicular lymphoma progresses slowly. It develops from B lymphocytes (B cells), which can clump up in lymph nodes.
When you were diagnosed, your physician probably told you what grade of lymphoma you have. Follicular lymphomas are graded either 1-2, grade 3a or 3b, which is an indication of how quickly the lymphoma is expected to grow. If your lymphoma is a grade 3b, it will probably grow faster than other grades.
If you have grades 1, 2 or 3a, you may be eligible for this clinical study.